Despite the availability of several safe and effective replacement therapies in the Hemophilia B market; the patients continue to experience bleeding, progressive joint diseases, and degraded quality of life. However, the Hemophilia B treatment market is expected to witness novel approaches that include siRNA, bispecific antibodies, and gene therapy in the coming years.
Key pharmaceutical companies in the Hemophilia B therapeutics market such as APCINTEX LIMITED, Novo Nordisk, Sanofi, Pfizer, Sangamo Therapeutics, Inc., Catalyst Biosciences, uniQure, Alnylam Pharmaceuticals, CSL Behring, and several others, are dynamically working in developing novel treatment therapies.
For more details, visit: Hemophilia B Market Forecast